The return of COVID-19 symptoms or a positive test after treatment with nirmatrelvir+ritonavir (Paxlovid, Pfizer) remains a rare and mild phenomenon that should not dissuade clinicians from recommending the potentially lifesaving drug combination, according to specialists, the CDC and the FDA.
In fact, based on the results of a retrospective study involving the health records of 13,644 people, the odds of both President Joe Biden and Anthony Fauci, MD, the director of the National